Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments

NEW YORK, May 10, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0850351/Autoimmune-Disorders-Therapeutics-Market-to-2017---Launch-of-Gilenya-and-Benlysta-to-Drive-the-Growth-of-Multiple-Sclerosis-and-Systemic-Lupus-Erythematosus-Therapeutic-Segments.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments

GBI Research's analysis shows that the autoimmune disorders therapeutics market, comprising RA, MS, psoriasis, IBDs (CD and UC) and SLE, was worth $16.9 billion in 2002 and grew at a Compound Annual Growth Rate (CAGR) of 7.5% to $30.2 billion in 2010. It is forecast to reach $61.4 billion in 2017, indicating a CAGR of 10.7% during the forecast period. The average Annual Cost of Treatment (ACT) for autoimmune disorders therapeutics is increasing, and is expected to reach $12,073 by 2017, resulting in steady increase of the overall market during the forecast period. Growth in the major markets of the US, the top five countries of Europe, and Japan was driven by new developments that have created more treatment options for these indications. The future of the global market is therefore based on the success of the drugs in the pipeline.

Scope

- Data and analysis on the autoimmune diseases therapeutics market in the leading geographies: the US, the top five countries of Europe (the UK, Germany, France, Italy, Spain), and Japan.- Annualized market data for the autoimmune diseases therapeutics market from 2002 to 2010, and forecast from 2010 to 2017.- Market data on the geographical landscape and therapeutic landscape, including market size, market share, ACT, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.- Generic share of the global autoimmune diseases therapeutics market and for the market of each indication that is covered in the report.- Key drivers and restraints that have had a significant impact on the market.- The competitive landscape of the global autoimmune diseases market including top companies benchmarking. The key companies studied in this report are Abbott Laboratories, Amgen Inc., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Merck, Pfizer Inc., Boehringer Ingelheim and Sanofi.- Key M&A activities and licensing agreements that took place from 2009 to 2011 in the autoimmune diseases therapeutics market.

Reasons to buy

- Align product portfolios to the markets with high growth potential.- Build effective strategies to launch pipeline products by identifying potential geographies.- Exploit in-licensing and out-licensing opportunities by identifying products that might fill portfolio gaps.- Develop key strategic initiatives by studying the key strategies of top competitors.- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.- Reinforce R&D pipelines by identifying new target mechanisms that can produce safer and more efficacious first-in-class molecules.1 Table of Contents1 Table of Contents 31.1 List of Tables 61.2 List of Figures 92 Autoimmune Disorders Therapeutics Market to 2017 - Introduction 122.1 GBI Research Report Guidance 133 Autoimmune Disorders Therapeutics Market to 2017 - Market Overview 143.1 Introduction 143.1.1 Revenue 143.1.2 Annual Cost of Treatment 153.1.3 Treatment Usage Pattern 164 Autoimmune Disorders Therapeutics Market to 2017: Geographical Landscape 184.1 Revenue Analysis by Geography 184.2 The US 194.2.1 Revenue 194.2.2 Annual Cost of Treatment 204.2.3 Treatment Usage Patterns 214.3 Top Five Countries of Europe 234.3.1 Revenue 234.3.2 Revenue by Country 244.3.3 Annual Cost of Treatment 254.3.4 Treatment Usage Patterns 264.4 Japan 284.4.1 Revenue 284.4.2 Annual Cost of Treatment 294.4.3 Treatment Usage Patterns 305 Autoimmune Disorders Therapeutics Market to 2017: Therapeutic Landscape 325.1 Rheumatoid Arthritis Therapeutics Market 325.1.1 Introduction 325.1.2 Revenue 325.1.3 Treatment Algorithm 365.1.4 Annual Cost of Treatment 365.1.5 Treatment Usage Pattern 375.1.6 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market 395.2 Multiple Sclerosis Therapeutics Market 415.2.1 Introduction 415.2.2 Revenue 425.2.3 Treatment Algorithm 465.2.4 Annual Cost of Treatment 475.2.5 Treatment Usage Patterns 485.2.6 Drivers and Barriers for Multiple Sclerosis Therapeutics Market 495.3 Psoriasis Therapeutics Market 515.3.1 Introduction 515.3.2 Revenue 525.3.3 Treatment Algorithm 555.3.4 Annual Cost of Treatment 555.3.5 Treatment Usage Pattern 565.3.6 Drivers and Barriers for Psoriasis Therapeutics Market 585.4 Inflammatory Bowel Disease Therapeutics Market 595.4.1 Introduction 595.4.2 Revenue 605.4.3 Treatment Algorithm 635.4.4 Annual Cost of Treatment 655.4.5 Treatment Usage Pattern 665.4.6 Drivers and Barriers for the Inflammatory Bowel Disease Therapeutics Market 685.5 Systemic Lupus Erythematosus Therapeutics Market 695.5.1 Introduction 695.5.2 Revenue 705.5.3 Treatment Algorithm 735.5.4 Annual Cost of Treatment 745.5.5 Treatment Usage Pattern 755.5.6 Drivers and Barriers for the Systemic Lupus Erythematosus Therapeutics Market 786 Autoimmune Disorders Therapeutics Market to 2017: Pipeline Analysis 806.1 Introduction 806.2 Autoimmune Disorders Therapeutics Market – Pipeline Assessment by Clinical Phase of Development 826.2.1 Filed Molecules 826.2.2 Phase III 856.2.3 Phase II 1076.2.4 Phase I 1156.2.5 Preclinical Phase 1186.2.6 Discovery Phase 1266.3 Profiles of Promising Molecules in the Autoimmune Disorders Therapeutics Market 1286.3.1 ABT-874 1286.3.2 Actemra 1286.3.3 Biferonex 1296.3.4 Fampyra 1306.3.5 Iguratimod 1306.3.6 LAS41002 1316.3.7 MAbThera 1326.3.8 Rebif 1336.3.9 Remicade 1346.3.10 Simponi 1356.3.11 T-614 1366.3.12 Zushima 1377 Autoimmune Disorders Therapeutics Market to 2017: Competitive Profiling 1387.1 Market Share Analysis 1387.2 Competitive Profiling 1387.2.1 Abbott Laboratories 1387.2.2 Pfizer Inc. 1397.2.3 Johnson & Johnson 1417.2.4 Biogen Idec Inc. 1427.2.5 Amgen Inc. 1437.2.6 Bayer AG 1457.2.7 Sanofi 1468 Autoimmune Disorders Therapeutics Market to 2017: Strategic Consolidations 1488.1 Overview 1488.2 Mergers and Acquisitions 1498.2.1 Segmentation by Indication 1498.2.2 Segmentation by Year 1508.2.3 Segmentation by Deal Type 1518.2.4 Segmentation by Deal Value 1528.2.5 Segmentation by Geography 1548.3 Co-development Deals 1558.3.1 Segmentation by Indication 1558.3.2 Segmentation by Year 1568.3.3 Segmentation by Value 1578.3.4 Segmentation by Geography 1588.3.5 Summary of Co-development Deals 1618.4 Licensing Deals 1638.4.1 Segmentation by Indication 1638.4.2 Segmentation by Year 1648.4.3 Segmentation by Value 1658.4.4 Segmentation by Geography 1668.4.5 Summary of Licensing Deals 1739 Autoimmune Disorders Therapeutics Market to 2017: Appendix 1769.1 Market Definitions 1769.2 Abbreviations 1769.3 Sources 1789.4 Research Methodology 1789.4.1 Coverage 1799.4.2 Secondary Research 1799.4.3 Primary Research 1799.5 Therapeutic Landscape 1809.5.1 Epidemiology-based Forecasting 1809.5.2 Market Size by Geography 1829.6 Geographical Landscape 1839.7 Pipeline Analysis 1839.8 Competitive Landscape 1839.9 Expert Panel Validation 1839.10 Contact Us 1839.11 Disclaimer 183

1.1 List of Tables

Table 1: Autoimmune Disorders Therapeutics Market, Global, Revenue ($bn), 2002–2010 14Table 2: Autoimmune Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2010–2017 14Table 3: Autoimmune Disorders Therapeutics Market, Global Annual Cost of Treatment ($), 2002–2010 15Table 4: Autoimmune Disorders Therapeutics Market, Global Annual Cost of Treatment ($), 2010–2017 15Table 5: Autoimmune Disorders Therapeutics Market, Treatment Usage Patterns (millions), 2002–2010 16Table 6: Autoimmune Disorders Therapeutics Market, Treatment Usage Patterns (millions), 2010–2017 17Table 7: Autoimmune Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2010 18Table 8: Autoimmune Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010–2017 19Table 9: Autoimmune Disorders Therapeutics Market, The US, Revenue ($bn), 2002–2010 20Table 10: Autoimmune Disorders Therapeutics Market, The US, Revenue ($bn), 2010–2017 20Table 11: Autoimmune Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002–2010 21Table 12: Autoimmune Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2010–2017 21Table 13: Autoimmune Disorders Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002–2010 22Table 14: Autoimmune Disorders Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010–2017 22Table 15: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002–2010 23Table 16: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010–2017 23Table 17: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002–2010 24Table 18: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010–2017 24Table 19: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002–2010 25Table 20: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010–2017 25Table 21: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002–2010 26Table 22: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2010–2017 27Table 23: Autoimmune Disorders Therapeutics Market, Japan, Revenue ($bn), 2002–2010 28Table 24: Autoimmune Disorders Therapeutics Market, Japan, Revenue Forecast ($bn), 2010–2017 28Table 25: Autoimmune Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002–2010 29Table 26: Autoimmune Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010–2017 29Table 27: Autoimmune Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002–2010 30Table 28: Autoimmune Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010–2017 31Table 29: Rheumatoid Arthritis Therapeutics Market, Global, Revenue ($bn), 2002–2010 32Table 30: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2010–2017 33Table 31: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2010 34Table 32: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010–2017 34Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 37Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 37Table 35: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2010 38Table 36: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010–2017 38Table 37: Multiple Sclerosis Therapeutics Market, Global, Revenue ($bn), 2002–2010 42Table 38: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecast ($bn), 2010–2017 43Table 39: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2010 44Table 40: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010–2017 44Table 41: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 47Table 42: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 47Table 43: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2010 48Table 44: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010–2017 49Table 45: Psoriasis Therapeutics Market, Global, Revenue ($bn), 2002–2010 52Table 46: Psoriasis Therapeutics Market, Global, Revenue Forecast ($bn), 2010–2017 52Table 47: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2010 53Table 48: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010–2017 54Table 49: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 56Table 50: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment($), 2010–2017 56Table 51: Psoriasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2010 57Table 52: Psoriasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010–2017 57Table 53: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue ($bn), 2002–2010 60Table 54: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Forecast ($bn), 2010–2017 60Table 55: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2010 61Table 56: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010–2017 62Table 57: Inflammatory Bowel Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 65Table 58: Inflammatory Bowel Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 65Table 59: Inflammatory Bowel Disease Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2010 66Table 60: Inflammatory Bowel Disease Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010–2017 67Table 61: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue ($m), 2002–2010 70Table 62: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m), 2010–2017 70Table 63: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2010 71Table 64: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010–2017 72Table 65: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2010 74Table 66: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Treatment ($), 2010–2017 74Table 67: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2010 75Table 68: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010–2017 76Table 69: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, New Drug Application Filed Molecules, 2011 82Table 70: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Phase III, 2011 85Table 71: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Phase II, 2011 107Table 72: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Phase I, 2011 115Table 73: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase, 2011 118Table 74: Autoimmune Disorders Therapeutics Market, Global, Pipeline Analysis, Discovery Phase, 2011 126Table 75: Autoimmune Disorders Therapeutics Market, Global, Deals by Type, (%), 2009-2011 148Table 76: Autoimmune Disorders Therapeutics Market, Global, M&A Deals by Indication, 2009-2011 149Table 77: Autoimmune Disorders Therapeutics Market, Global, Number of M&A Deals, 2009-2011 150Table 78: Autoimmune Disorders Therapeutics Market, Global, M&A Deals by Deal Type (%), 2009-2011 151Table 79: Autoimmune Disorders Therapeutics Market, Global, M&A Deals, by Value ($m), 2009-2011 152Table 80: Autoimmune Disorders Therapeutics Market, Global, Number of Co-Development Deals, 2009-2011 156Table 81: Autoimmune Disorders Therapeutics Market, Global, Co-Developments Deals by Value, 2009-2011 157Table 82: Autoimmune Disorders Therapeutics Market, Global, Co-Development Deals by Geography, 2009-2011 158Table 83: Autoimmune Disorders Therapeutics Market, Global, Co-development Deals by Geography, 2009-2011 159Table 84: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Indication, 2009-2011 164Table 85: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Indication (%), 2009-2011 164Table 86: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Value, 2009-2011 165Table 87: Autoimmune Disorders Therapeutics Market, Licensing Deals by Geography, 2009-2011 167

1.2 List of Figures

Figure 1: Autoimmune Disorders Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017 14Figure 2: Autoimmune Disorders Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 15Figure 3: Autoimmune Disorders Therapeutics Market, Treatment Usage Patterns (millions), 2002–2017 16Figure 4: Autoimmune Disorders Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002–2017 18Figure 5: Autoimmune Disorders Therapeutics Market, The US, Revenue ($bn), 2002–2017 19Figure 6: Autoimmune Disorders Therapeutics Market, The US, Annual Cost of Treatment ($), 2002–2017 20Figure 7: Autoimmune Disorders Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002–2017 21Figure 8: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002–2017 23Figure 9: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2002–2017 24Figure 10: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002–2017 25Figure 11: Autoimmune Disorders Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (millions), 2002–2017 26Figure 12: Autoimmune Disorders Therapeutics Market, Japan, Revenue Forecast ($bn), 2002–2017 28Figure 13: Autoimmune Disorders Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002–2017 29Figure 14: Autoimmune Disorders Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2002–2017 30Figure 15: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017 32Figure 16: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2017 33Figure 17: Rheumatoid Arthritis Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and 2017 35Figure 18: Rheumatoid Arthritis Therapeutics Market, Rheumatoid Arthritis, Treatment Algorithm 36Figure 19: Rheumatoid Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 36Figure 20: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2017 37Figure 21: Rheumatoid Arthritis Therapeutics Market, Drivers and Barriers 39Figure 22: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017 42Figure 23: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2017 43Figure 24: Multiple Sclerosis Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and 2017 45Figure 25: Multiple Sclerosis Therapeutics Market, Multiple Sclerosis, Treatment Algorithm 46Figure 26: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 47Figure 27: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2017 48Figure 28: Multiple Sclerosis Therapeutics Market, Drivers and Barriers 50Figure 29: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017 52Figure 30: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2017 53Figure 31: Psoriasis Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and 2017 54Figure 32: Psoriasis Therapeutics Market, Psoriasis, Treatment Algorithm 55Figure 33: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 55Figure 34: Psoriasis Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002–2017 56Figure 35: Psoriasis Therapeutics Market, Drivers and Barriers 58Figure 36: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Forecasts ($bn), 2002–2017 60Figure 37: Inflammatory Bowel Disease Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2017 61Figure 38: Inflammatory Bowel Disease Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and 2017 62Figure 39: Inflammatory Bowel Disease Therapeutics Market, Ulcerative Colitis, Treatment Algorithm 63Figure 40: Inflammatory Bowel Disease Therapeutics Market, Crohn's Disease, Treatment Algorithm 64Figure 41: Inflammatory Bowel Disease Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 65Figure 42: Inflammatory Bowel Disease Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2017 66Figure 43: Inflammatory Bowel Disease Therapeutics Market, Global, Drivers and Barriers 68Figure 44: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($m), 2002–2017 70Figure 45: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002–2017 71Figure 46: Systemic Lupus Erythematosus Therapeutics Market, Global, Branded & Generic Market Share (%), 2010 and 2017 72Figure 47: Systemic Lupus Erythematosus Therapeutics Market, Systemic Lupus Erythematosus, Treatment Algorithm 73Figure 48: Systemic Lupus Erythematosus Therapeutics Market, Global, Annual Cost of Treatment ($), 2002–2017 74Figure 49: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002–2017 75Figure 50: Systemic Lupus Erythematosus Therapeutics Market, Global, Drivers and Barriers 79Figure 51: Autoimmune Disorders Therapeutics Market, Global, R&D Pipeline by Indications (%), 2011 80Figure 52: Autoimmune Disorders Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 81Figure 53: Autoimmune Disorders Therapeutics Market, Global, Market Share of Top Companies (%), 2010 138Figure 54: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Abbott, 2011 139Figure 55: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Pfizer Inc., 2011 140Figure 56: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Johnson & Johnson, 2011 141Figure 57: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Biogen Idec Inc., 2011 143Figure 58: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Amgen Inc., 2011 144Figure 59: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Bayer AG, 2011 145Figure 60: Autoimmune Disorders Therapeutics Market, Global, SWOT Analysis, Sanofi, 2011 147Figure 61: Autoimmune Disorders Therapeutics Market, Global, Deals by Type, (%), 2009-2011 148Figure 62: Autoimmune Disorders Therapeutics Market, Global, M&A Deals by Indication (%), 2009-2011 149Figure 63: Autoimmune Disorders Therapeutics Market, Global, Number of M&A Deals, 2009-2011 150Figure 64: Autoimmune Disorders Therapeutics Market, Global, M&A Deals by Deal Type (%), 2009-2011 151Figure 65: Autoimmune Disorders Therapeutics Market, M&A Deals, by Value (%) 2009-2011 152Figure 66: Autoimmune Disorders Therapeutics Market, M&A Deals, by Geography (%), 2009-2011 154Figure 67: Autoimmune Disorders Therapeutics Market, Global, Co-Development Deals by Indication (%), 2009-2011 155Figure 68: Autoimmune Disorders Therapeutics Market, Global, Number of Co-Development Deals, 2009-2011 156Figure 69: Autoimmune Disorders Therapeutics Market, Global, Co-Developments Deals by Value (%), 2009-2011 157Figure 70: Autoimmune Disorders Therapeutics Market, Global, Co-Development Deals by Geography (%), 2009-2011 158Figure 71: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Indication (%), 2009-2011 163Figure 72: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Indication (%), 2009-2011 164Figure 73: Autoimmune Disorders Therapeutics Market, Global, Licensing Agreements by Value (%), 2009-2011 165Figure 74: Autoimmune Disorders Therapeutics Market, Licensing Deals by Geography (%), 2009-2011 166Figure 75: GBI Research Market Forecasting Model 182

Companies mentioned

Abbott Laboratories

Pfizer Inc.

Johnson & Johnson

Biogen Idec Inc.

Amgen Inc.

Bayer AG

Sanofi

More  

Check our  

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker